(Bloomberg) -- Pfizer Inc.’s Tukysa, when given as part of the initial treatment for an advanced form of breast cancer, delayed tumor growth by more than eight months, according to a study that may ...

(Bloomberg) -- A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of blood disorders. The death occurred on Dec. 14 after the ...

(Bloomberg) -- A next-generation treatment for breast cancer from Pfizer Inc. and Arvinas Inc. posted disappointing results in a final-stage study, a potential setback for a drug Pfizer once called a ...

A U.S. FDA panel of independent experts beat back an effort by Pfizer (NYSE:PFE) to expand the patient population for its prostate cancer treatment Talzenna (talazoparib). Members of the Oncologic ...

Pfizer (PFE) is reducing its Swiss workforce, with plans to cut its employee count to about 70 by the end of 2025 from 300 amid a broader cost-cutting drive, Bloomberg News reported, citing people ...

Pfizer (NYSE:PFE) has generated £2.5B ($3.24B) after selling its entire stake in Haleon (NYSE:HLN), the consumer healthcare company it established with the British pharmaceutical giant GSK (GSK) in ...